John Henry, MD
Cardiovascular Disease · Omaha, NENPI 1831157213
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,338 of the $78,888 with a category attached, or 71.4%. Amgen accounts for 83.8% of it on its own, with 47 other manufacturers making up the rest. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 835 payments — averaging $94.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$66K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$1K
- Pfizer$985
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$888
- plus $7K from 42 others
Across 18 payments — averaging $152.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$2K
- Chiesi USA, Inc.$1K
What the payments were for
- Speaking & faculty fees$56,33871%
- Travel & lodging$5,1777%
- Food & beverage$17,35722%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,888 in reported general payments places this provider in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 553 | $543,586 |
| VyndamaxTafamidis | 14 | $362,941 |
| EntrestoSacubitril/Valsartan | 271 | $294,157 |
| XareltoRivaroxaban | 78 | $74,404 |
| Repatha SureclickEvolocumab | 80 | $61,099 |
| JardianceEmpagliflozin | 35 | $43,584 |
| Praluent PenAlirocumab | 48 | $34,072 |
| Metoprolol Succinate | 708 | $8,975 |
| Ranolazine ErRanolazine | 96 | $7,352 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $7,350 |
| Ezetimibe | 277 | $6,384 |
| Nebivolol Hcl | 121 | $4,685 |
| Atorvastatin Calcium | 507 | $4,385 |
| Flecainide Acetate | 107 | $3,897 |
| Rosuvastatin Calcium | 254 | $3,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $985 | $906,527567 claims |
| NovartisEntresto | $1,757 | $294,157271 claims |
| Johnson & JohnsonXarelto | $610 | $74,40478 claims |
| Boehringer IngelheimJardiance | $833 | $43,58435 claims |
| Esperion Therapeutics, Inc.Nexlizet | $221 | $7,35011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
- Shiva PonamgiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.